Stockreport

Humacyte: Positive News For Symvess At Last, But Long-Term Threats Persist [Seeking Alpha]

Humacyte, Inc.  (HUMA) 
PDF Symvess is the only FDA-approved human-derived bioengineered blood vessel, but Q3 revenue was just $700k, and uptake remains limited. HUMA's funding runway is constra [Read more]